Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Xencor from a buy rating to a hold rating in a research note on Saturday, November 16th. BidaskClub raised shares of Xencor from a buy rating to a strong-buy rating in a research note on Saturday, December 7th. Mizuho reaffirmed a buy rating on shares of Xencor in a research note on Tuesday, November 5th. Guggenheim began coverage on shares of Xencor in a research note on Wednesday, November 20th. They set a hold rating on the stock. Finally, Leerink Swann cut their target price on shares of Xencor from $52.00 to $44.00 and set an outperform rating on the stock in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $43.90.
XNCR stock opened at $37.36 on Friday. The firm’s 50-day moving average price is $37.00 and its two-hundred day moving average price is $37.48. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -28.52 and a beta of 1.38. The company has a current ratio of 8.92, a quick ratio of 8.92 and a debt-to-equity ratio of 0.01. Xencor has a 12-month low of $27.75 and a 12-month high of $46.33.
Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.40. The firm had revenue of $21.76 million for the quarter, compared to analyst estimates of $4.62 million. Xencor had a net margin of 21.60% and a return on equity of 5.84%. Equities analysts predict that Xencor will post 0.5 EPS for the current year.
In other news, major shareholder John S. Stafford III sold 120,324 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $41.64, for a total transaction of $5,010,291.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder John S. Stafford III sold 37,951 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $38.68, for a total transaction of $1,467,944.68. The disclosure for this sale can be found here. 4.33% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP boosted its holdings in shares of Xencor by 185.4% in the 1st quarter. First Trust Advisors LP now owns 69,783 shares of the biopharmaceutical company’s stock valued at $2,167,000 after buying an additional 45,331 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Xencor by 64.6% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 26,809 shares of the biopharmaceutical company’s stock valued at $1,097,000 after buying an additional 10,520 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Xencor by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,911 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 1,160 shares in the last quarter. Aperio Group LLC acquired a new stake in Xencor in the 2nd quarter worth approximately $152,000. Finally, DekaBank Deutsche Girozentrale boosted its stake in Xencor by 63.7% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 29,800 shares of the biopharmaceutical company’s stock worth $1,207,000 after purchasing an additional 11,600 shares in the last quarter. 92.43% of the stock is owned by hedge funds and other institutional investors.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Xencor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xencor and related companies with MarketBeat.com’s FREE daily email newsletter.